Mod GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Rhodesia's Unilateral Declaration of Independence (UDI) was a statement adopted by the Cabinet of Rhodesia on 11 November 1965, announcing that Rhodesia (previously known as Southern Rhodesia), a British crown colony in southern Africa that had governed itself since 1923, now regarded itself as an independent sovereign state. The culmination of a protracted dispute between the British and Rhodesian governments regarding the terms under which the latter could become fully independent, it was the first unilateral break from the United Kingdom by one of its colonies since the United States Declaration of Independence in 1776. The UK, the Commonwealth, and the United Nations all deemed Rhodesia's UDI illegal, and economic sanctions, the first in the UN's history, were imposed on the breakaway colony. With the help of the Commonwealth Secretariat, members of the Commonwealth were able to cooperate and advise Rhodesian Africans on policy. Amid near-complete international isolation, Rhodesia continued as an unrecognised state with the assistance of South Africa and (until 1974) Portugal. The Rhodesian government, which mostly comprised members of the country's white minority of about 5%, was indignant when, amid the UK colonial government's Wind of Change policies of decolonisation, African colonies to the north without comparable experience of self-rule quickly advanced to independence during the early 1960s while Rhodesia was refused sovereignty under the newly ascendant principle of "no independence before majority rule" ("NIBMAR").
In this role, she serves as an advocate and liaison for basic science researchers working in clinical departments to help facilitate the combination of “basic research” which seeks to answer fundamental scientific questions and “translational research” that seeks to put those findings to use, for example in a clinical setting. In 2020, she was named director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, becoming the first African-American director of a basic science department, and the first Black woman to chair any department, at Johns Hopkins University School of Medicine. Outside of Johns Hopkins, Bumpus chaired the National Institute of Health (NIH)'s Xenobiotic and Nutrient Disposition and Action study section and served as a science commissioner and member of Washington, D.C.’s Science Advisory Board. She was an associate editor of the journal Drug Metabolism and Disposition. She has been strongly involved with the American Society for Pharmacology and Experimental Therapeutics (ASPET), where she served as secretary and treasurer and president.
== Education and training == Verdine received a Bachelor of Science in chemistry from Saint Joseph's University and a PhD in chemistry from Columbia University, working under Koji Nakanishi and Maria Tomasz. He held an NIH postdoctoral fellowship in molecular biology at MIT and Harvard Medical School, and joined the faculty of Harvard University in 1988.
San Donato district is between Corso Francia, Corso Lecce, Corso Potenza, Via Nole, the Parco Dora and Corso Principe Oddone. It was populated since the medieval era, but becomes bigger during the 19th century, prospering around the canal Canale di San Donato, which does not exist anymore, currently replaced by the central street of the district, Via San Donato. Buildings in the district are relatively recent (around 1820), except for the oldest group of small houses in the Brusachœr neighbourhood (Palazzo Forneris building) along Via Pacinotti near the small Piazza Paravia. The conservation of the street and of this old building influences the straightness of Via San Donato, which makes a slight curve to result in parallel with Via Pacinotti before ending in central Piazza Statuto square. Main church of the district is the Chiesa di Nostra Signora del Suffragio e Santa Zita, which with its 83 m (272 ft) height of its bell tower, is well known to be the fifth tallest structure in the city of Turin, after the Mole Antonelliana, the Intesa-Sanpaolo skyscraper, the Torre Littoria and the two pennons of the Juventus Stadium. The church is hosting the Istituto Suore Minime di Nostra Signora del Suffragio and it was promoted and designed by Francesco Faà di Bruno. The legend says, that he wanted to build the tallest bell tower of the town and put a clock on the top, to all the poor people to know the time for free. The small building near the church is what remains of Casa Tartaglino, a small residential building which was also extended and modified by Faa di Bruno.
Sources: en.wikipedia.org
=== Biopolymer and nanotechnology applications === Aramwit coedited Nanotechnology in Drug Delivery with Glen S. Kwon and Melgardt M. de Villiers, exploring nanotechnology-based drug delivery systems and their application for the delivery of small molecules, proteins, peptides, oligonucleotides, and genes. Her research highlighted that alginate/chitosan beads enhance the stability and bioavailability of mulberry-extracted anthocyanin, with 0.05% chitosan solution proving most effective for encapsulation and gastric resistance, while Eugenol-embedded calcium citrate nanoparticles (Eu-CaCit NPs) show potential as a biocompatible topical delivery system, improving dermal penetration and reducing skin irritation.
PP cells are able to produce pancreatic polypeptide through transcription and translation of the PPY gene. Once it is produced, pancreatic polypeptide is shown to be a 36 amino acid long peptide that can be sent out to different areas within the pancreas or organism. Pancreatic polypeptide cells are most active and secrete more pancreatic polypeptide after a meal with high protein, fasting, physical activity, and acute hypoglycemia. These same cells are inhibited by somatostatin, an inhibitory gastrointestinal hormone, and the presence of glucose.
=== December === 1 December – Everton Football Club launch an appeal against the decision to dock them ten Premier League points. 2 December – Havering London Borough Council reverses its decision to cancel the display of Hanukkah candles outside its town hall, having previously said the display would not go ahead because of "escalating tensions from the conflict in the Middle East". Police declare a major incident in Cumbria, which is affected by heavy snowfall. As much as 30 cm has fallen by the following day. 5 December – Junior doctors in England will stage further strike action after rejecting the latest pay offer, the British Medical Association confirms, with a three-day strike scheduled to begin on 20 December and a six-day strike scheduled to begin on 3 January 2024. A woman, later named as Lianne Gordon, is shot dead in an incident in east London. A teenage boy and a man are also injured in the shooting. 6 December – Mayor of the West Midlands Andy Street confirms the Home Secretary has authorised his application to have the powers of the West Midlands Police and Crime Commissioner subsumed into his mayoral role from May 2024. 7 December – An inquest into the death of Ruth Perry rules that an Ofsted report "likely contributed" to the head teacher taking her life in January 2023. Six former Metropolitan Police officers are given suspended sentences after sending racist, sexist and homophobic WhatsApp messages. 9 December – A 16-year-old boy is charged with the murder of Lianne Gordon.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.